Cost-effective non-additive GWAS across 2329 diseases in 500,349 individuals
Abstract Drug candidates supported by genetic evidence are more likely to succeed in clinical trials, with genome-wide association studies (GWAS) providing a key source of such evidence. Standard GWAS approaches assume additive effects of alleles on the phenotype, but non-additive models have also s...
שמור ב:
| Principais autores: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Portfolio
2025-12-01
|
| סדרה: | Nature Communications |
| גישה מקוונת: | https://doi.org/10.1038/s41467-025-67277-4 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|